Drug intelligence / Profile preview

LMA.CAR-T

Development stage: Preclinical
Lead developer: HaemaLogiX
Modality: CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

LMA.CAR-T is a chimeric antigen receptor (CAR) T-cell immunotherapy developed by HaemaLogiX. It is currently in preclinical development for the treatment of multiple myeloma and AL amyloidosis. This therapy involves genetically modifying a patient's own T cells to express a CAR that specifically recognizes and binds to the lambda myeloma antigen (LMA), which is expressed on cancerous plasma cells. Upon binding, the engineered T cells are activated to target and destroy these LMA-positive cancer cells. HaemaLogiX is an Australian biotech company focused on developing novel immunotherapies for blood cancers and B-cell disorders.

Other names: Lambda Myeloma Antigen CAR-T cell therapy

Targets

Cλ (Immunoglobulin lambda light chain constant region)

Beyond the preview

Go deeper on LMA.CAR-T.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LMA.CAR-T.

Explore the full profile